- Home
- KRG vs APGE Comparison
KRG vs APGE Comparison
Compare KRG & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRG | APGE |
|---|---|---|
| Founded | 1971 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.7B |
| IPO Year | 2004 | 2023 |
Fundamental Metrics
Financial Performance| Metric | KRG | APGE |
|---|---|---|
| Price | $24.32 | $77.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $25.33 | ★ $101.89 |
| AVG Volume (30 Days) | ★ 2.0M | 999.2K |
| Earning Date | 02-10-2026 | 11-10-2025 |
| Dividend Yield | ★ 4.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $856,786,000.00 | N/A |
| Revenue This Year | $1.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $37.97 | ★ N/A |
| Revenue Growth | ★ 3.78 | N/A |
| 52 Week Low | $18.52 | $26.20 |
| 52 Week High | $24.69 | $80.99 |
Technical Indicators
Market Signals| Indicator | KRG | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 66.22 | 58.67 |
| Support Level | $23.36 | $72.56 |
| Resistance Level | $24.20 | $80.34 |
| Average True Range (ATR) | 0.32 | 3.34 |
| MACD | 0.00 | -0.52 |
| Stochastic Oscillator | 89.67 | 54.92 |
Price Performance
Historical ComparisonAbout KRG Kite Realty Group Trust
Kite Realty Group Trust specializes in owning, operating, acquiring, developing, and redeveloping high-quality open-air shopping centers and mixed-use assets. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.